JPWO2021133904A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021133904A5 JPWO2021133904A5 JP2022539136A JP2022539136A JPWO2021133904A5 JP WO2021133904 A5 JPWO2021133904 A5 JP WO2021133904A5 JP 2022539136 A JP2022539136 A JP 2022539136A JP 2022539136 A JP2022539136 A JP 2022539136A JP WO2021133904 A5 JPWO2021133904 A5 JP WO2021133904A5
- Authority
- JP
- Japan
- Prior art keywords
- bacteria
- capsule
- dosage form
- solid dosage
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007909 solid dosage form Substances 0.000 claims description 138
- 241000894006 Bacteria Species 0.000 claims description 116
- 239000002775 capsule Substances 0.000 claims description 74
- 239000008185 minitablet Substances 0.000 claims description 52
- 239000003814 drug Substances 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 36
- 239000003826 tablet Substances 0.000 claims description 31
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 28
- 239000002702 enteric coating Substances 0.000 claims description 27
- 238000009505 enteric coating Methods 0.000 claims description 27
- 239000008177 pharmaceutical agent Substances 0.000 claims description 23
- 230000001580 bacterial effect Effects 0.000 claims description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 230000000813 microbial effect Effects 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 11
- 229940127557 pharmaceutical product Drugs 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 239000002662 enteric coated tablet Substances 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 4
- 229920002494 Zein Polymers 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 229920002301 cellulose acetate Polymers 0.000 claims description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 4
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 4
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 4
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 230000003362 replicative effect Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000005019 zein Substances 0.000 claims description 4
- 229940093612 zein Drugs 0.000 claims description 4
- 241000192125 Firmicutes Species 0.000 claims description 3
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 229920000856 Amylose Polymers 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 238000009010 Bradford assay Methods 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 208000027244 Dysbiosis Diseases 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 229920001800 Shellac Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 241001148470 aerobic bacillus Species 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- WZNRVWBKYDHTKI-UHFFFAOYSA-N cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 230000007140 dysbiosis Effects 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- IWVKTOUOPHGZRX-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.COC(=O)C(C)=C IWVKTOUOPHGZRX-UHFFFAOYSA-N 0.000 claims description 2
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 230000003448 neutrophilic effect Effects 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- -1 poly(vinyl acetate phthalate) Polymers 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000004208 shellac Substances 0.000 claims description 2
- 229940113147 shellac Drugs 0.000 claims description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 2
- 235000013874 shellac Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 125000005591 trimellitate group Chemical group 0.000 claims description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962954153P | 2019-12-27 | 2019-12-27 | |
| US62/954,153 | 2019-12-27 | ||
| PCT/US2020/066828 WO2021133904A1 (en) | 2019-12-27 | 2020-12-23 | Solid dosage forms containing bacteria and microbial extracellular vesicles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023510158A JP2023510158A (ja) | 2023-03-13 |
| JPWO2021133904A5 true JPWO2021133904A5 (enrdf_load_html_response) | 2024-01-05 |
Family
ID=74626080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539136A Pending JP2023510158A (ja) | 2019-12-27 | 2020-12-23 | 細菌及び微生物細胞外小胞を含有する固形剤形 |
Country Status (13)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202216178A (zh) * | 2020-06-11 | 2022-05-01 | 美商艾弗洛生物科技股份有限公司 | 使用巨型球菌屬物種治療疾病及障礙之組成物及方法 |
| WO2022020326A1 (en) * | 2020-07-21 | 2022-01-27 | Evelo Biosciences, Inc. | Veillonella parvula strain as an oral therapy for neuroinflammatory diseases |
| WO2023049268A1 (en) * | 2021-09-24 | 2023-03-30 | Evelo Biosciences, Inc. | Solid dosage forms containing bacteria and microbial extracellular vesicles |
| EP4429684A1 (en) * | 2021-12-16 | 2024-09-18 | Enterobiome Inc. | Pharmaceutical composition for preventing or treating cancer or inflammatory disease |
| CN115252651B (zh) * | 2022-06-08 | 2024-06-07 | 广州知易生物科技有限公司 | 嗜粘蛋白阿克曼菌在制备防治高血压的组合物中的应用和含有其的组合物 |
| CR20250068A (es) * | 2022-08-29 | 2025-03-27 | Lilly Co Eli | Composiciones para suministro oral |
| CN116509900B (zh) * | 2022-12-01 | 2023-11-10 | 佛山科学技术学院 | 益生菌或其细胞外囊泡在制备防治胃溃疡产品中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775536A (en) | 1986-02-24 | 1988-10-04 | Bristol-Myers Company | Enteric coated tablet and process for making |
| US5292522A (en) | 1989-06-20 | 1994-03-08 | Rohm Gmbh | Aqueous film coating agent for solid medicaments |
| US5047258A (en) | 1989-07-14 | 1991-09-10 | Sterling Drug Inc. | Aqueous spray-coating process |
| US6623759B2 (en) | 1996-06-28 | 2003-09-23 | Astrazeneca Ab | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
| DE19631084A1 (de) | 1996-08-01 | 1998-02-05 | Basf Ag | Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut |
| US6312728B1 (en) | 1998-07-07 | 2001-11-06 | Cascade Development, Inc. | Sustained release pharmaceutical preparation |
| EP1101490B1 (en) | 1998-07-28 | 2005-04-13 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
| DE19937361A1 (de) * | 1999-08-12 | 2001-02-22 | Merck Patent Gmbh | Orale Darreichungsform |
| US20040028737A1 (en) | 2002-08-12 | 2004-02-12 | Kopran Research Laboratories Limited | Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same |
| DE10260919A1 (de) | 2002-12-20 | 2004-07-01 | Röhm GmbH & Co. KG | Verfahren zur Herstellung von überzogenen Arzneiformen und Nahrungsergänzungsmitteln mit Konzentrationsgradienten im Überzug |
| US20070065513A1 (en) | 2003-10-31 | 2007-03-22 | Avi Avramoff | Stable lansoprazole formulation |
| US9149439B2 (en) | 2005-03-21 | 2015-10-06 | Sandoz Ag | Multi-particulate, modified-release composition |
| DE102005032806A1 (de) | 2005-07-12 | 2007-01-18 | Röhm Gmbh | Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten |
| CN101209247B (zh) * | 2006-12-27 | 2011-12-14 | 天津中新药业集团股份有限公司 | 一种结肠靶向制剂的制备方法 |
| CN101757042A (zh) * | 2009-05-25 | 2010-06-30 | 北京诚创康韵医药科技有限公司 | 一种益生菌微丸制剂及其制备 |
| AU2013347805C1 (en) * | 2012-11-23 | 2018-06-28 | Seres Therapeutics, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| US8906668B2 (en) * | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| EP2961387B1 (en) | 2013-03-01 | 2017-08-23 | BPSI Holdings, LLC. | Delayed release film coatings containing calcium silicate and substrates coated therewith |
| CA3013541C (en) * | 2013-03-14 | 2021-01-19 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| JP2021512106A (ja) * | 2018-01-31 | 2021-05-13 | エヴェロ バイオサイエンシズ，インコーポレーテッド | ラクノスピラ科（Ｌａｃｈｎｏｓｐｉｒａｃｅａｅ）の細菌を使用して免疫障害を処置するための組成物及び方法 |
-
2020
- 2020-12-23 US US17/789,427 patent/US20230355689A1/en active Pending
- 2020-12-23 JP JP2022539136A patent/JP2023510158A/ja active Pending
- 2020-12-23 MX MX2022007943A patent/MX2022007943A/es unknown
- 2020-12-23 WO PCT/US2020/066828 patent/WO2021133904A1/en not_active Ceased
- 2020-12-23 CN CN202080090020.6A patent/CN114945357A/zh active Pending
- 2020-12-23 AR ARP200103650A patent/AR122353A1/es not_active Application Discontinuation
- 2020-12-23 KR KR1020227025604A patent/KR20220128362A/ko active Pending
- 2020-12-23 CA CA3165418A patent/CA3165418A1/en active Pending
- 2020-12-23 EP EP20853582.3A patent/EP4081195A1/en not_active Withdrawn
- 2020-12-23 AU AU2020413225A patent/AU2020413225A1/en active Pending
- 2020-12-23 BR BR112022012514A patent/BR112022012514A2/pt not_active Application Discontinuation
- 2020-12-25 TW TW109146331A patent/TW202135783A/zh unknown
-
2022
- 2022-07-19 CO CONC2022/0010242A patent/CO2022010242A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220016041A1 (en) | Once Daily Formulations Of Tetracyclines | |
| EP1638529B1 (en) | Oral extended-release composition | |
| JP5412491B2 (ja) | 促進剤を含む固体経口剤形 | |
| JP4053604B2 (ja) | 時間特異的放出制御型投与製剤及びその製法 | |
| TW589174B (en) | Agent for treating high-risk impaired glucose tolerance | |
| US20070128276A1 (en) | Controlled release compositions comprising nimesulide | |
| BG105203A (bg) | Фармацевтична таблетка с разграждащо се в черватапокритие и метод за получаване | |
| JP3633936B2 (ja) | センナ剤形 | |
| US20090111788A1 (en) | Antibiotic compositions of modified release and process of production thereof | |
| CN1118571A (zh) | 比沙可啶剂型 | |
| Saigal et al. | Site specific chronotherapeutic drug delivery systems: A patent review | |
| TW201740932A (zh) | 美沙拉 的口服醫藥組成物 | |
| ES2408343A2 (es) | Composiciones farmacéuticas que comprenden hidromorfona y naloxona | |
| CA3200952A1 (en) | Sustained release solid dosage forms for modulating the colonic microbiome | |
| JP2004507487A (ja) | 腸疾患治療薬 | |
| JPWO2021133904A5 (enrdf_load_html_response) | ||
| CN109152772B (zh) | 烟酰胺的口服药物组合物 | |
| CN101130062A (zh) | 一种脑蛋白多肽的结肠靶向给药制剂及其制备方法 | |
| CN100413502C (zh) | 治疗高血压药物 | |
| WO2018158465A9 (de) | Pharmazeutische zusammensetzung umfassend pankreatin und einen lipasehaltigen überzug | |
| KR101504199B1 (ko) | 위장관 표적 지향형 한방 제제의 제조방법 및 상기 제조방법에 의해 제조된 한방 제제 | |
| JPWO2022217030A5 (enrdf_load_html_response) | ||
| EP4565232A1 (en) | A stable tablet-in-tablet composition for nausea vomiting in pregnancy | |
| AU2018214291A1 (en) | Composition comprising immediate release and extended release Capecitabine | |
| HK40075535B (en) | Dosage form for use in treating or preventing of a disease |